Increased plasma fibrin gel porosity in patients with type I diabetes during continuous subcutaneous insulin infusion

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 6, 2003, Pages 1195-1201

  JoRneskog G ^a,c   Hansson, L O ^a   Wallen, N H ^b,c   Yngen, M ^b   Blomback M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Continuous subcutaneous insulin infusion; Glycemic control; Plasma fibrin gel structure; Plasma fibrinogen

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; FIBRIN; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPID;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD EXAMINATION; FEMALE; HUMAN; INFLAMMATION; INFUSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; POROSITY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; FIBRIN; FIBRINOGEN; HEMATOLOGIC TESTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INFUSIONS, PARENTERAL; INSULIN; LIPIDS; MALE; POROSITY;

EID: 2142752962     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00301.x     Document Type: Article

References (44)

1. The Diabetes Control and Complication Trial Resarch Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
2. United Kingdom Prospective Diabetes Study Group, UK prospective diabetes study 33. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk for complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
3. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-50.
4. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-10.
5. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
6. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
7. Ridker PM. Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic disease. Eur Heart J 1998; 19: 1119-21.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
9. Ferry JD, Morrison PR. Preparations and properties of serum and plasma proteins. The conversion of human fibrinogen to fibrin under various conditions. J Am Chem Soc 1947; 69: 388-400.
10. Nair CH, Azhar A, Wilson JD, Dhall DP. Studies on fibrin network structure in human plasma. Part II-Clinical application: diabetes and antidiabetic drugs. Thromb Res 1991; 64: 477-85.
11. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel net work characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-5.
12. Collet JP, Mishal Z, Lesty C, Mirshahi M, Peynet J, Baumelou A, Bensman A, Soria J, Soria C. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost 1999; 82: 1482-9.
13. Jörneskog G, Fagrell B, Fatah K, Hessel B, Johnsson H, Brismar K, Blombäck M. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-23.
14. Weets I, Gorus FK, Gerlo E. Evaluation of an immunoturbidimetric assay for hemoglobin A1c on a Cobas Mira S Analyser. Eur J Clin Chem Clin Biochem 1996; 34: 449-53.
15. Hemmilä I, Dakubu S, Mukkala V-M, Siitari H, Lövgren T. Europium as a lable in time-resolved immunofluorometric assays. Anal Biochem 1984; 137: 335-43.
16. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-41.
17. Blombäck B. On the properties of fibrinogen and fibrin. Arkiv Kemi 1958; 2: 99-113.
18. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyck R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 5: 521-38.
19. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Åslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
20. Blombäck B, Okada M. Fibrin gel structure and clotting time. Thromb Res 1982; 25: 51-70.
21. Okada M, Blombäck B. Factors influencing fibrin gel structure studied by flow measurements. Ann NY Acad Sci 1983; 408: 233-53.
22. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
23. Siebenlist KR, Mosesson MW. Progressive cross-linking of fibrin g chains increases resistance to fibrinolysis. J Biol Chem 1994; 269: 28414-9.
24. Sakata Y, Mimuro J, Aoki N. Differential binding of plasminogen to cross-linked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency. Blood 1984; 63: 1393-401.
25. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-40.
26. Schalkwijk CG, Poland DC, van DijkW, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VW, Stehouwer CD. Plasma concentrations of C-reactive protein is increased in Type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-7.
27. Myrup B, de Maat M, Rossing P, Gram J, Kluft C, Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Res 1996; 81: 485-90.
28. De Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996; 121: 185-91.
29. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999; 20: 1039-43.
30. Massi-Benedetti M, Federici MO. Cardiovascular risk factors in type 2 diabetes: the role of hyperglycemia. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl. 4): S120-3.
31. Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausl W, Wagner OF. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulindependent diabetes mellitus. J Endocrinol Metab 1996; 81: 4313-7.
32. Marfella R, Espoito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giugliano D. Circulating adhesion molecules in humans. Role of hyperglycemia and hyperinsulinemia. Circulation 2000; 101: 2247-51.
33. Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998; 30: 146-9.
34. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with Type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Int Med 2000; 248: 67-76.
35. Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res 1995; 6: 449-56.
36. Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LE, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996; 45: 1253-8.
37. Mecklenburg RS, Benson EA, Benson JW Jr, Blumenstein BA, Fredlund PN, Guinn TS, Metz RJ, Nielsen RL. Long-term metabolic control with insulin pump therapy: report of experience with 127 patients. N Engl J Med 1985; 313: 465-8.
38. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin Lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001; 24: 1722-7.
39. Stout RW. Insulin and atheroma. 20 year perspective. Lancet 1990; 13: 631-54.
40. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, Quertermous T, King GL. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 1991; 266: 23251-6.
41. Shoemaker JK, Bonen A. Vascular actions of insulin in health and disease. Can J Appl Physiol 1995; 20: 127-54.
42. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87: 746-61.
43. Villanueva GB, Allen N. Demonstration of altered anti-thrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients. Diabetes 1988; 37: 1103-7.
44. Lutjens A, te Velde AA, vd Veen EA, vd Meer J. Glycosylation of human fibrinogen in vivo. Diabetologia 1985; 28: 87-9.